Возможности липафереза в комплексном лечении атеросклероза
Download
2. Амбатьело С. Г. Диагностика и лечение больных мультифокальным атеросклерозом: Автореф. дис. … д-ра мед. наук. – М., 2002.
3. Аронов Д. М. Лечение и профилактика атеросклероза. – М., 2000. – С. 9–16.
4. Бокерия Л. А., Гудкова Р. Г. Сердечно-сосудистая хирургия. – 2002. – М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН, 2003.
5. Гендель Л. Л., Гуревич К. Я., Белоцерковский М. В. Авторское свидетельство № 4940987. – СССР, 1991.
6. Гуревич К. Я., Климов А. Н., Белоцерковский М. В. и др. Перспективы экстракорпоральной гемокоррекции в лечении атеросклероза // Эфферентная тер. – 1998. – Т. 4, № 1. – С. 17–20.
7. Климов А. Н., Белоцерковский М. В., Гуревич К. Я. и др. Курсовое применение плазмообменов экстракорпорально модифицированной аутоплазмой на основе технологии криоплазмосорбции // Там же. – 1995. – Т. 1, № 3. – С. 29–36.
8. Коновалов Г. А., Звездкин П. В., Хаютина Т. Л. и др. Гиполипидемическая терапия и реоферез при дислипопротеидемиях // Consilium medicum. – 2003. – Т. 5, № 11. – С. 22–31.
9. Коновалов Г. А., Осипов С. Г., Кушекбаева А. Е. и др. Влияние плазмафереза, плазмосорбции и иммуносорбции липопротеидов низкой плотности на состояние гуморального иммунитета у больных с наследственной гиперхолестеринемией // Тер. арх. – 1990. – Т. 62, № 1. – С. 39–42.
10. Коновалов Г. А., Чебышев А. Н., Кухарчук В. В. и др. Влияние длительного применения афереза липопротеидов низкой плотности на состояние больных тяжелыми формами наследственной гиперхолестеринемии (15-летнее наблюдение) // Кремлевская мед. Клин. вестн. – 1999. – № 4. – С. 57–64.__
11. Лопаткин Н. А., Лопухин Ю. М. Эфферентные методы в медицине. – М., 1989. – С. 184.
12. Лопухин Ю. М., Арчаков А. И., Владимиров Ю. А., Коган Э. М. Холестериноз. – М., 1983.
13. Макеева Т. И., Гуревич К. Я., Константинов В. О. и др. Место плазмообмена экстракорпорально модифицированной аутоплазмой в комплексном лечении больных ишемической болезнью сердца // Эфферентная тер. – 1996. – Т. 2, № 3. – С. 24–29.
14. Макеева Т. И., Гуревич К. Я., Олейник И. А., Ва- сильева Л. Е. Место плазмообмена экстракорпорально модифицированной аутоплазмой в комплексном лечении больных ишемической болезнью сердца (сообщение 2) // Там же. – 1997. – Т. 3, № 3. – С. 30–35.
15. Маргулис Е. Я., Савченко В. Г., Васильев С. А. и др. Клиническая эффективность метода экстракорпоральной гепаринопреципитации плазменных белков (селективного плазмафереза) у больных с иммунокомплексной патологией // Тер. арх. – 1985. – № 5. – С. 125–131.
16. Новые Европейские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний // Доказательная кардиология. – 2003. – № 2. – С. 34–36.
17. Оганов Р. Г., Масленникова Г. Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине 20 столетия: тенденции, возможные причины, перспективы // Кардиология. – 2000. – № 6.– С. 4–8.
18. Adachi H., Niwa A., Shinoda T. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis // Artif. Organ. – 1995. – Vol. 19. – P. 1243–1247.
19. Baumbauer R., Schiefl R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies // Ther. Apher. – 2000. – Vol. 4. – P. 213–217.
20. Blessing F. J., Jaeger B., Wang Y. et al. Heparinmediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion // Thromb. Res. – 2005. – Vol. 15. – P. 39–43.
21. Blessing F. J., Jaeger B. R., Oberhoffer M. et al. Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H. E. L. P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses) // Z. Kardiol. – 2003. – Bd. 92 (Beil. 3). – S. 42–47.
22. Bosch T., Gahr S., Belschner U. et al. for the DALI Study Group. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions // Ther. Apher. Dial. – 2006. – Vol. 10, № 3. – P. 210–218.
23. Bosch T., Schmidt B., Kleophas W. et al. LDL hemoperfusion – a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis in patients // Artif. Organs. – 1997. – Vol. 21. – P. 1060–1065.
24. Drager L. J., Julius U., Kraenzle K. et al. DALI – the first human whole-blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results // Eur. J. Clin. Invest. – 1998. – Vol. 28. – P. 994–1002.
25. Eisenhauer T., Amstrong V. W., Wieland H. et al. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system // Klin. Woch. – 1987. – Vol. 65. – P. 161–168.
26. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts) // Eur. Heart J. – 2003. – Vol. 24. – P. 1601–1610.
27. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. – 2001. – Vol. 285. – P. 2486–2497.
28. Illigworth D. Treatment of hyperlipidemia // Brit. Med. Bull. – 1990. – Vol. 46, № 4. – P. 1025–1058.
29. Jaeger B. R., Kreuzer E., Knez A. et al. Case reports on emergency treatment of cardiovascular syndromes through heparin-mediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage // Ther. Apher. – 2002. – Vol. 6. – P. 394–398.
30. Jaeger B. R., Seidel D. Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the HELP system // Herz. – 2001. – Bd. 26. – S. 531–544.
31. Knisel W., Di Nicuolo A., Pfohl M. et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system // J. Int. Med. – 1993. – Vol. 234. – P. 479–487.
32. Kobayashi S., Oka M., Moriya H. LDL-apheresis reduces P-Selectin, CRP and fibrinogen–possible important implications for improving atherosclerosis // Ther. Apher. Dial. – 2006. – Vol. 10, № 3. – P. 219–223.
33. Kroon A. A., Aengevaeren W. R., van der Werf T. et al. LDL-Apferesis Atherosclerosis Regression Study (LAARS). Effects of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis // Circulation. – 1996. – Vol. 93. – P. 1826–1835.
34. Lupien P.-J., Moorjani S., Award J. A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography // Lancet. – 1976. – Vol. 1. – P. 1261–1265.
35. Mabuchi H., Michishita I., Takeda M. et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis) // Atheroscler. – 1989. – Vol. 68. – P. 19–26.
36. Matsuzaki M., Hiramori K., Imaizumi T. et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: The Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART) // J. Amer. Coll. Cardiol. – 2002. – Vol. 40, № 2. – P. 220–227.
37. Morelli F., Carlier P., Giannini G. et al. Hypercholesterolemia and LDL apheresis // Int. J. Artif. Organs. – 2005. – Vol. 28, № 10. – P. 1025–1031.
38. Nishimura S., Sekiguchi M., Kano T. et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS) // Atherosclerosis. – 1999. – Vol. 144. – P. 409–417.
39. Norda R., Stegmayr B. G. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group // Transfus. Apheresis. Sci. – 2001. – Vol. 24. – P. 49–55.
40. Parhofer K. G., Geiss H. C., Schwandt P. Efficacy of different low-density lipoprotein apheresis methods // Ther. Apher. – 2000. – Vol. 4. – P. 382–385.
41. Pokrovsky S. N., Ezhov M. V., Il’ina L. N. et al. Association of lipoprotein(a) excess with early vein graft occlusion in middle-aged men undergoing coronary artery bypass surgery // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 126, № 4. – P. 1071–1075.
42. Richter W. O., Donner M. G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation // Ther. Apher. – 1999. – Vol. 3. – P. 203–208.
43. Richter W. O., Jacob B. G., Ritter M. M. et al. Threeyear treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorbtion with polyclonal apolipoprotein B antibodies // Metabolism. – 1993. – Vol. 42. – P. 888–894.
44. Schmaldienst S., Banyai S., Stulnig T. M. et al. Prospective randomized cross-over comparison oh three LDL-apheresis system in statin pretreated patients with familial hypercholesterolemia // Atherosclerosis. – 2000. – Vol. 151. – P. 493–499.
45. Schuff-Werner P., Schutz E., Beyer H. Fibrinogen lowering by apheresis: efficiency of different methods and possible clinical implications// Jap. J. Apheresis. – 1997. – Vol. 16, № 1. – P. 317–318.
46. Schuff-Werner P. Extracorporeal hemorheotherapy with selective plasma protein elimination // Ibid. – 1997. – Vol. 16, № 1. – P. 25–30.
47. Seidel D. LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy // Z. Kardiol. – 2003. – Bd. 92 (Beil. 3). – S. 6–27.
48. Sinzinger H., Bednar J., Granegger S. et al. LDLapheresis and concomitant ACE-inhibitor therapy // Atherosclerosis. – 1994. – Vol. 105. – P. 115–116.
49. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia // Lancet. – 1981. – Vol. 2. – P. 1005–1007.
50. Sulowicz W., Stompor T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy // Nephrol. Dial. Transplant. – 2003. – Vol. 18. – P. 59–62.
51. The Scandinavian Simvastatin Survival Study Droup: Randomized trial of Cholesterol Lowering ion 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S) // Lancet. – 1994. – Vol. 344. – P. 1383–1389.
52. Thiery J., Seidel D. Safety and effectiveness of longterm LDL-apheresis in patients at high risk // Curr. Opin. Lipidol. – 1998. – Vol. 9. – P. 521–526.
53. Thompsen J., Thompson P. D. A systematic review of LDL apheresis in the treatment of cardiovascular disease // Atherosclerosis. – 2006. – Vol. 189, № 1. – P. 31–38.
54. Thompson G. R., Lowenthal R., Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia // Lancet. – 1975. – Vol. 1. – P. 1208–1211.
55. Thompson G. R., Maher V. M., Matthews S. et al. Familial Hypercholesterolaemia Regression Study: a randomized trial of low-density-lipoprotein apferesis (FHRS) // Lancet. – 1995. – Vol. 345. – P. 811–816.
56. Thompson G. R., Myant N. B., Kilpatrick D. et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia // Brit. Heart J. – 1980. – Vol. 43. – P. 680–688.
57. Thompson G. R. Handbook of hyperlipidaemia. – London: MSD Co., 1989. – P. 236.
58. Thompson G. R. LDL apheresis // Atherosclerosis. – 2003. – Vol. 167. – P. 1–13.
59. Tsuchida H., Shigematsu H., Ishimaru S. et al. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS) // Int. Angiol. – 2006. – Vol. 25, № 3. – P. 287–292.
60. Waters D., Higginson L., Gladstone P. et al. Canadian coronary Atherosclerosis Intervention Trial // Circulation. – 1994. – Vol. 89. – P. 959–968.
61. Yokoyama S., Hayashi R., Satani M. et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolaemia // Arteriosclerosis. – 1985. – Vol. 5. – P. 613–622.
References
1. Агапов А. А., Власова Э. Е., Акчурин Р. С. и др. Ранние и одногодичные результаты коронарного шунтирования; связь с дислипопротеидемией // Кардиология. – 1996. – № 12. – С. 34–39.2. Амбатьело С. Г. Диагностика и лечение больных мультифокальным атеросклерозом: Автореф. дис. … д-ра мед. наук. – М., 2002.
3. Аронов Д. М. Лечение и профилактика атеросклероза. – М., 2000. – С. 9–16.
4. Бокерия Л. А., Гудкова Р. Г. Сердечно-сосудистая хирургия. – 2002. – М.: Изд-во НЦССХ им. А. Н. Бакулева РАМН, 2003.
5. Гендель Л. Л., Гуревич К. Я., Белоцерковский М. В. Авторское свидетельство № 4940987. – СССР, 1991.
6. Гуревич К. Я., Климов А. Н., Белоцерковский М. В. и др. Перспективы экстракорпоральной гемокоррекции в лечении атеросклероза // Эфферентная тер. – 1998. – Т. 4, № 1. – С. 17–20.
7. Климов А. Н., Белоцерковский М. В., Гуревич К. Я. и др. Курсовое применение плазмообменов экстракорпорально модифицированной аутоплазмой на основе технологии криоплазмосорбции // Там же. – 1995. – Т. 1, № 3. – С. 29–36.
8. Коновалов Г. А., Звездкин П. В., Хаютина Т. Л. и др. Гиполипидемическая терапия и реоферез при дислипопротеидемиях // Consilium medicum. – 2003. – Т. 5, № 11. – С. 22–31.
9. Коновалов Г. А., Осипов С. Г., Кушекбаева А. Е. и др. Влияние плазмафереза, плазмосорбции и иммуносорбции липопротеидов низкой плотности на состояние гуморального иммунитета у больных с наследственной гиперхолестеринемией // Тер. арх. – 1990. – Т. 62, № 1. – С. 39–42.
10. Коновалов Г. А., Чебышев А. Н., Кухарчук В. В. и др. Влияние длительного применения афереза липопротеидов низкой плотности на состояние больных тяжелыми формами наследственной гиперхолестеринемии (15-летнее наблюдение) // Кремлевская мед. Клин. вестн. – 1999. – № 4. – С. 57–64.__
11. Лопаткин Н. А., Лопухин Ю. М. Эфферентные методы в медицине. – М., 1989. – С. 184.
12. Лопухин Ю. М., Арчаков А. И., Владимиров Ю. А., Коган Э. М. Холестериноз. – М., 1983.
13. Макеева Т. И., Гуревич К. Я., Константинов В. О. и др. Место плазмообмена экстракорпорально модифицированной аутоплазмой в комплексном лечении больных ишемической болезнью сердца // Эфферентная тер. – 1996. – Т. 2, № 3. – С. 24–29.
14. Макеева Т. И., Гуревич К. Я., Олейник И. А., Ва- сильева Л. Е. Место плазмообмена экстракорпорально модифицированной аутоплазмой в комплексном лечении больных ишемической болезнью сердца (сообщение 2) // Там же. – 1997. – Т. 3, № 3. – С. 30–35.
15. Маргулис Е. Я., Савченко В. Г., Васильев С. А. и др. Клиническая эффективность метода экстракорпоральной гепаринопреципитации плазменных белков (селективного плазмафереза) у больных с иммунокомплексной патологией // Тер. арх. – 1985. – № 5. – С. 125–131.
16. Новые Европейские рекомендации по профилактике и лечению сердечно-сосудистых заболеваний // Доказательная кардиология. – 2003. – № 2. – С. 34–36.
17. Оганов Р. Г., Масленникова Г. Я. Сердечно-сосудистые заболевания в Российской Федерации во второй половине 20 столетия: тенденции, возможные причины, перспективы // Кардиология. – 2000. – № 6.– С. 4–8.
18. Adachi H., Niwa A., Shinoda T. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis // Artif. Organ. – 1995. – Vol. 19. – P. 1243–1247.
19. Baumbauer R., Schiefl R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies // Ther. Apher. – 2000. – Vol. 4. – P. 213–217.
20. Blessing F. J., Jaeger B., Wang Y. et al. Heparinmediated extracorporeal LDL precipitation treating a peripheral arterial disease patient suffering from repeated postoperative bypass occlusion // Thromb. Res. – 2005. – Vol. 15. – P. 39–43.
21. Blessing F. J., Jaeger B. R., Oberhoffer M. et al. Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H. E. L. P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses) // Z. Kardiol. – 2003. – Bd. 92 (Beil. 3). – S. 42–47.
22. Bosch T., Gahr S., Belschner U. et al. for the DALI Study Group. Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions // Ther. Apher. Dial. – 2006. – Vol. 10, № 3. – P. 210–218.
23. Bosch T., Schmidt B., Kleophas W. et al. LDL hemoperfusion – a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis in patients // Artif. Organs. – 1997. – Vol. 21. – P. 1060–1065.
24. Drager L. J., Julius U., Kraenzle K. et al. DALI – the first human whole-blood low-density lipoprotein and lipoprotein(a) apheresis system in clinical use: procedure and clinical results // Eur. J. Clin. Invest. – 1998. – Vol. 28. – P. 994–1002.
25. Eisenhauer T., Amstrong V. W., Wieland H. et al. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system // Klin. Woch. – 1987. – Vol. 65. – P. 161–168.
26. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts) // Eur. Heart J. – 2003. – Vol. 24. – P. 1601–1610.
27. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. – 2001. – Vol. 285. – P. 2486–2497.
28. Illigworth D. Treatment of hyperlipidemia // Brit. Med. Bull. – 1990. – Vol. 46, № 4. – P. 1025–1058.
29. Jaeger B. R., Kreuzer E., Knez A. et al. Case reports on emergency treatment of cardiovascular syndromes through heparin-mediated low-density lipoprotein/fibrinogen precipitation: a new approach to augment cerebral and myocardial salvage // Ther. Apher. – 2002. – Vol. 6. – P. 394–398.
30. Jaeger B. R., Seidel D. Hyperlipoproteinemia and LDL apheresis. Clinical experiences with the HELP system // Herz. – 2001. – Bd. 26. – S. 531–544.
31. Knisel W., Di Nicuolo A., Pfohl M. et al. Different effects of two methods of low-density lipoprotein apheresis on the coagulation and fibrinolytic system // J. Int. Med. – 1993. – Vol. 234. – P. 479–487.
32. Kobayashi S., Oka M., Moriya H. LDL-apheresis reduces P-Selectin, CRP and fibrinogen–possible important implications for improving atherosclerosis // Ther. Apher. Dial. – 2006. – Vol. 10, № 3. – P. 219–223.
33. Kroon A. A., Aengevaeren W. R., van der Werf T. et al. LDL-Apferesis Atherosclerosis Regression Study (LAARS). Effects of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis // Circulation. – 1996. – Vol. 93. – P. 1826–1835.
34. Lupien P.-J., Moorjani S., Award J. A new approach to the management of familial hypercholesterolaemia: removal of plasma cholesterol based on the principle of affinity chromatography // Lancet. – 1976. – Vol. 1. – P. 1261–1265.
35. Mabuchi H., Michishita I., Takeda M. et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis) // Atheroscler. – 1989. – Vol. 68. – P. 19–26.
36. Matsuzaki M., Hiramori K., Imaizumi T. et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: The Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART) // J. Amer. Coll. Cardiol. – 2002. – Vol. 40, № 2. – P. 220–227.
37. Morelli F., Carlier P., Giannini G. et al. Hypercholesterolemia and LDL apheresis // Int. J. Artif. Organs. – 2005. – Vol. 28, № 10. – P. 1025–1031.
38. Nishimura S., Sekiguchi M., Kano T. et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS) // Atherosclerosis. – 1999. – Vol. 144. – P. 409–417.
39. Norda R., Stegmayr B. G. Apheresis registry in Sweden: scope, techniques and indications for treatment. A report from the Swedish apheresis study group // Transfus. Apheresis. Sci. – 2001. – Vol. 24. – P. 49–55.
40. Parhofer K. G., Geiss H. C., Schwandt P. Efficacy of different low-density lipoprotein apheresis methods // Ther. Apher. – 2000. – Vol. 4. – P. 382–385.
41. Pokrovsky S. N., Ezhov M. V., Il’ina L. N. et al. Association of lipoprotein(a) excess with early vein graft occlusion in middle-aged men undergoing coronary artery bypass surgery // J. Thorac. Cardiovasc. Surg. – 2003. – Vol. 126, № 4. – P. 1071–1075.
42. Richter W. O., Donner M. G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation // Ther. Apher. – 1999. – Vol. 3. – P. 203–208.
43. Richter W. O., Jacob B. G., Ritter M. M. et al. Threeyear treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorbtion with polyclonal apolipoprotein B antibodies // Metabolism. – 1993. – Vol. 42. – P. 888–894.
44. Schmaldienst S., Banyai S., Stulnig T. M. et al. Prospective randomized cross-over comparison oh three LDL-apheresis system in statin pretreated patients with familial hypercholesterolemia // Atherosclerosis. – 2000. – Vol. 151. – P. 493–499.
45. Schuff-Werner P., Schutz E., Beyer H. Fibrinogen lowering by apheresis: efficiency of different methods and possible clinical implications// Jap. J. Apheresis. – 1997. – Vol. 16, № 1. – P. 317–318.
46. Schuff-Werner P. Extracorporeal hemorheotherapy with selective plasma protein elimination // Ibid. – 1997. – Vol. 16, № 1. – P. 25–30.
47. Seidel D. LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy // Z. Kardiol. – 2003. – Bd. 92 (Beil. 3). – S. 6–27.
48. Sinzinger H., Bednar J., Granegger S. et al. LDLapheresis and concomitant ACE-inhibitor therapy // Atherosclerosis. – 1994. – Vol. 105. – P. 115–116.
49. Stoffel W., Borberg H., Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia // Lancet. – 1981. – Vol. 2. – P. 1005–1007.
50. Sulowicz W., Stompor T. LDL-apheresis and immunoadsorption: novel methods in the treatment of renal diseases refractory to conventional therapy // Nephrol. Dial. Transplant. – 2003. – Vol. 18. – P. 59–62.
51. The Scandinavian Simvastatin Survival Study Droup: Randomized trial of Cholesterol Lowering ion 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S) // Lancet. – 1994. – Vol. 344. – P. 1383–1389.
52. Thiery J., Seidel D. Safety and effectiveness of longterm LDL-apheresis in patients at high risk // Curr. Opin. Lipidol. – 1998. – Vol. 9. – P. 521–526.
53. Thompsen J., Thompson P. D. A systematic review of LDL apheresis in the treatment of cardiovascular disease // Atherosclerosis. – 2006. – Vol. 189, № 1. – P. 31–38.
54. Thompson G. R., Lowenthal R., Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia // Lancet. – 1975. – Vol. 1. – P. 1208–1211.
55. Thompson G. R., Maher V. M., Matthews S. et al. Familial Hypercholesterolaemia Regression Study: a randomized trial of low-density-lipoprotein apferesis (FHRS) // Lancet. – 1995. – Vol. 345. – P. 811–816.
56. Thompson G. R., Myant N. B., Kilpatrick D. et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia // Brit. Heart J. – 1980. – Vol. 43. – P. 680–688.
57. Thompson G. R. Handbook of hyperlipidaemia. – London: MSD Co., 1989. – P. 236.
58. Thompson G. R. LDL apheresis // Atherosclerosis. – 2003. – Vol. 167. – P. 1–13.
59. Tsuchida H., Shigematsu H., Ishimaru S. et al. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS) // Int. Angiol. – 2006. – Vol. 25, № 3. – P. 287–292.
60. Waters D., Higginson L., Gladstone P. et al. Canadian coronary Atherosclerosis Intervention Trial // Circulation. – 1994. – Vol. 89. – P. 959–968.
61. Yokoyama S., Hayashi R., Satani M. et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolaemia // Arteriosclerosis. – 1985. – Vol. 5. – P. 613–622.
